Maria Martinelli, APRN
Adult Health · Kent, OHNPI 1124792031
Payments from drug & device makers
Across 109 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$294
- Novo Nordisk$232
- AstraZeneca$176
- GSK$160
- Boehringer Ingelheim$128
- Astellas Pharma US Inc$123
- plus $863 from 19 others
What the payments were for
- Food & beverage$1,976100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $294 |
| Novo Nordisk | 15 | $232 |
| AstraZeneca | 11 | $176 |
| GSK | 10 | $160 |
| Boehringer Ingelheim | 8 | $128 |
| Astellas Pharma US Inc | 6 | $123 |
| Pfizer | 6 | $114 |
| Bayer | 5 | $112 |
| Dexcom, Inc. | 4 | $83 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| Lilly USA, LLC | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Mylan Specialty L.p. | 2 | $47 |
| Johnson & Johnson | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Dynavax Technologies Corporation | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Amgen | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Organon | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $16 |
How this compares
$1,976 in reported general payments places this provider in the 80th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 153 | $148,382 |
| TrulicityDulaglutide | 101 | $125,700 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 119 | $93,142 |
| EliquisApixaban | 77 | $83,861 |
| OzempicSemaglutide | 30 | $35,165 |
| MounjaroTirzepatide | 31 | $33,067 |
| XareltoRivaroxaban | 27 | $28,698 |
| FarxigaDapagliflozin Propanediol | 27 | $24,676 |
| JanuviaSitagliptin Phosphate | 36 | $23,600 |
| LinzessLinaclotide | 23 | $16,261 |
| RybelsusSemaglutide | 11 | $11,101 |
| Spiriva HandihalerTiotropium Bromide | 13 | $8,906 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $7,936 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,615 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $59 | $158,767132 claims |
| Boehringer IngelheimJardiance | $128 | $148,382153 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $160 | $113,342158 claims |
| PfizerEliquis | $114 | $83,86177 claims |
| Novo NordiskOzempic, Rybelsus | $232 | $46,26641 claims |
| AstraZenecaFarxiga, Symbicort | $176 | $31,42246 claims |
| Johnson & JohnsonXarelto | $46 | $28,69827 claims |
| AbbVieLinzess | $294 | $16,26123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,184 adult health providers in Ohio.
Other adult health in Kent
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Margaret TiktinCleveland$105K
- Teresa ShafferBoardman$102K
- Jesse McClainYoungstown$79K
- Lucretia LongColumbus$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.